We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GVS Filter Technology Gets Warning Letter on Testing, Quality Violations

GVS Filter Technology Gets Warning Letter on Testing, Quality Violations

April 24, 2015

The FDA has warned the UK branch of GVS Filter Technology for failures in product-testing and quality control.

The Bologna, Italy-based company has branches worldwide and manufactures air and liquid filters for medical devices such as anesthesia machines and nebulizers.

Quality control failures cited in the Jan. 23 letter included three cases where nonconforming products required reworking and re-evaluation, but device history records did not document that the work was performed.

The FDA said the company’s quality control procedure doesn’t describe requirements for documenting how nonconforming products are handled, and doesn’t require documentation of justification and approval for use of nonconforming products.

The letter said five nonconformance reports didn’t adequately document disposition of nonconforming products. Records showed discrepancies in the number of devices determined to be “scrap” or for “use-as-is.”

Following inspection, GVS Filter updated its nonconformance procedure to document disposal actions. But the company’s response didn’t include corrections to faulty nonconformance reports or evidence that records created before the update were reviewed, the letter states.

FDA also criticized the company for process validation failures. A test report listed a batch of sample filters as “pass” after they failed to meet the specification of 99.97 percent. In another instance, a sampling plan for sodium-chloride efficiency testing was described with no documentation of the statistical technique used to verify product characteristics.

Although the company later updated its lot history record forms, it didn’t show evidence of retrospective review of other lot history records to determine that all acceptance tests were conducted properly. It also didn’t analyze “the potential risks to safety and effectiveness of the filters” that might result from deficient tests that weren’t recorded.

The company’s CAPA violations include failure to adequately document all corrective activities.

FDA noted two CAPA records for customer complaints and three nonconformance related CAPAs. It said the company didn’t document validation of the corrective actions to ensure that these actions didn’t adversely affect the devices in question.

The company is actively working to address all topics in the warning letter and is committed to providing the highest quality products in compliance with FDA regulations, a spokesman told IDDM.

Read the warning letter at www.fdanews.com/04-16-15-GVS.pdf. — Charlotte Astor

Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing